Showing 411-420 of 1851 results for "".
Drug Prices Soar, Amgen Files BLA for Biosimilar to Humira
https://practicaldermatology.com/topics/practice-management/dermwiretv-drug-prices-soar-amgen-files-bla-for-biosimilar-to-humira/18672/In this edition, Amgen Submits ABP 501—first Adalimumab biosimilar; prices for dermatology drugs jump and a survey explores patient knowledge of antibiotic resistance. Also, Almirall acquires Veltin from Sitefel/GSK.Innovation in Dermatology Entrepreneurship
https://practicaldermatology.com/topics/practice-management/innovation-in-dermatology-entrepreneurship/18912/Entrepreneurship in dermatology is "in a good spot," says William Ju, MD, President of Advancing Innovation in Dermatology. Dermatology is a high-growth field, supported by patient demand and globalization and scientific advancements.Thoughts on HIPAA
https://practicaldermatology.com/topics/practice-management/thoughts-on-hipaa/19206/Michael Sacopulos, JD discusses HIPAA compliance for aesthetic practices. (Recorded June 2013)FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.On New Therapeutics and Real Sushi
https://practicaldermatology.com/series/the-practical-dermatology-podcast/on-new-therapeutics-and-real-sushi/32849/The latest news and updates, plus E. James Song, MD, FAAD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss the 2025 outlook for new therapeutics and play "Two Truths and a Lie." Dr. Song says he has been a wrestler, a jazz musician, and a sushi cheFDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.PDT in Action: New Options for Actinic Keratosis
https://practicaldermatology.com/series/pdt-in-practice/pdt-in-action-new-options-for-actinic-keratosis/20210/Dr. Joel L. Cohen, a board-certified dermatologist practicing in Denver, shares insights into the use of photodynamic therapy (PDT) in his practice and how PDT has impacted the options for the treatment of actinic keratosis.Photoprotection in Diverse Patient Populations
https://practicaldermatology.com/programs/practical-dermatology/photoprotection-in-diverse-patient-populations/18196/In part one of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Drs. Andrew Alexis, Corey Hartman, and Janiene Luke discuss photoprotection and why it matters for all patients.The Use of Lasers and Energy-Based Devices in Patients with Richly Pigmented Skin
https://practicaldermatology.com/programs/practical-dermatology/the-use-of-lasers-and-energy-based-devices-in-patients-with-richly-pigmented-skin/18199/In the last of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Andrew Alexis, MD, a dermatologist from New York City and the President of the Skin of Color Society, Corey Hartman, MD, a dermatologist in Birmingham, Alabama, and Janiene Luke, MD, a dermatoloClosing Gaps in Care for People of Color with Psoriatic Disease
https://practicaldermatology.com/programs/practical-dermatology/closing-gaps-in-care-for-people-of-color-with-psoriatic-disease/18190/Black, Hispanic, Asian, and other people of color with plaque psoriasis and psoriatic arthritis often face delayed diagnosis, misdiagnosis, and limited access to testing, treatment, and care. Determi-Nation, a new initiative sponsored by Janssen Pharmaceuticals, aims to change this. Patient advocate